Hospital Universitario Virgen de las Nieves

Granada, Andalusia 18015

3 studies enrolling now · 8 studies all time

What they study most

Colorectal Cancer (CRC), Coronary Heart Disease (CHD), Hypersensitivity Pneumonitis, Idiopathic Pulmonary Fibrosis (IPF), Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Interstitial Lung Disease With Systemic Sclerosis, Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Melanoma, Metastatic Colorectal Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS)

Studies at this site

• An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) — Recruiting now
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — Recruiting now
• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma — Recruiting now
• Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation — Completed
• A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis — Running, not enrolling
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery — Running, not enrolling
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma — Running, not enrolling